Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucagon Jun 28 | 2019Xeris/Insulet Partnership Discontinued? Ph2 Xeris Glucagon Bariatric Surgery TrialPurchase Blast
$599
Posted in: Other, SGLT2i Jun 27 | 2019HF Trial Draft Guidance Issued by FDA; Public Hearing in July 2019Purchase Blast
$599
Posted in: GLP-1RA, SGLT2i Jun 27 | 2019High-dose Trulicity Topline Results; Jardiance Fast Track Designation for HFPurchase Blast
$599
Posted in: Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, SGLT2i Jun 24 | 2019DECLARE CHMP Decision This Week; Sanofi BS-Aspart Filed in EU? CHMP Agenda HighlightsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Jun 20 | 2019Adocia's Pramlintide + Insulin Combo (ADO09) Ph1b Trial Posted on CT.govPurchase Blast
$599
Posted in: GLP-1RA Jun 19 | 2019New Semaglutide High-Dose T2DM Ph3 Trial (SUSTAIN FORTE)Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other Jun 19 | 2019Sanofi R&D Re-focusing; R&D Layoffs in France and GermanyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Jun 19 | 2019New Tirzepatide vs. Ozempic H2H Ph3 Trial (SURPASS-2)Purchase Blast
$599
Posted in: Glucagon Jun 17 | 2019Xeris Glucagon Ph3 Top-line Data vs. Novo's GlucaGenPurchase Blast
$599
Posted in: Insulin Delivery Jun 13 | 2019Connected Care: Biocorp Receives CE Mark for MallyaPurchase Blast
$599
Posted in: GLP-1RA Jun 11 | 2019Oral Sema Market-Shaping; Novo's ADA 2019 PIONEER PresentationPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jun 10 | 2019ADA 2019 Key Press Releases (June 9 and 10)Purchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA Jun 10 | 2019Lilly REWIND and Tirzepatide Comments From ADA 2019 Investor CallPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery Jun 10 | 2019Novo ADA 2019 Investor Event HighlightsPurchase Blast$599
Posted in: GLP-1RA Jun 10 | 2019Thoughts on REWIND; GLP-1RA Dynamics to Remain the SamePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Jun 10 | 2019Medtronic Calls Out Tandem and Dexcom; Medtronic ADA 2019 Investor EventPurchase Blast$599
Posted in: Bolus Insulin Jun 09 | 2019URLi ISRs Could Sting LLY; Ph3 Results MixedPurchase Blast